Among the proteins implicated in age‑related neurodegeneration, TDP‑43 has taken on growing importance: its misfolding and mislocalization are now linked to frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and are estimated to be present in more than half of Alzheimer’s cases. Faster cognitive decline, greater brain atrophy, and worsening memory loss are all associated with TDP-43. Now, researchers at the University of California, San Diego (UCSD), are testing a gene‑therapy strategy designed not to remove TDP‑43, but to help neurons withstand its toxicity. In a study published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the team reports that systemic delivery of a gene called SynCav1 to brain cells protected cognition and preserved neuronal structure in a mouse model of TDP‑43 proteinopathy. The study is titled, “Systemic delivery of synapsin-promoted caveolin-1 overexpression ameliorates pathological TDP-43–induced cognitive decline and neurodegenerative changes.” The approach centers on caveolin‑1, a scaffolding protein that organizes membrane signaling domains and supports neuronal resilience. The researchers packaged SynCav1 into a modified AAV vector capable of crossing the blood–brain barrier—a notable departure from many CNS gene therapies that require direct injections into brain tissue. Once delivered, SynCav1 boosted caveolin‑1 expression across the brain and spinal cord. “Many therapies for neurodegenerative disease focus on removing toxic proteins, but neurons are also losing their ability to cope with that stress,” said senior author Brian Head, PhD, professor of anesthesiology at UCSD School of Medicine and research career scientist at the Veterans Affairs San Diego Healthcare System. “Our findings…
